Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The company's pipeline consists of small molecule product candidates that target cancer.
Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification.
The company was founded in 2014 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.59 Decreased by -11.32% | -0.63 Increased by +6.35% |
| May 2, 24 | -0.59 Decreased by -18.00% | -0.55 Decreased by -7.27% |
| Feb 27, 24 | -0.55 Decreased by -12.24% | -0.55 |
| Nov 2, 23 | -0.50 Increased by +5.66% | -0.55 Increased by +9.09% |
| Aug 3, 23 | -0.53 Decreased by -1.92% | -0.55 Increased by +3.64% |
| May 10, 23 | -0.50 Decreased by -2.04% | -0.54 Increased by +7.41% |
| Feb 23, 23 | -0.49 Increased by 0.00% | -0.57 Increased by +14.04% |
| Nov 3, 22 | -0.53 Decreased by -6.00% | -0.56 Increased by +5.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -54.40 M Decreased by -40.94% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -50.84 M Decreased by -36.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -49.52 M Decreased by -59.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.27 M Increased by +N/A% | -42.79 M Decreased by -28.32% | Decreased by -3.37 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -38.60 M Decreased by -5.49% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -37.17 M Decreased by -5.21% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -31.00 M Increased by +5.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -33.34 M Decreased by -1.83% | Decreased by N/A% Decreased by N/A% |